View live charts, options flow & technicals for McKesson Corporation →
Open Dashboard
McKesson Corporation (MCK) is a healthcare company in the medical distribution industry with $410.98B in trailing revenue trading at a 23.5× trailing P/E — analyst consensus: buy.
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Key Statistics
Market Cap
$102.66B
Revenue (TTM)
$410.98B
EPS (TTM)
$37.52
EPS (Fwd est.)
$50.47
Employees
41,600
Trailing P/E
23.47
Forward P/E
17.45
PEG Ratio
1.68
Price / Sales
0.25
Price / Book
-24.09
EV / EBITDA
15.87
Beta (5Y)
0.31
Analyst Consensus
Consensus
Buy
Analyst Price Target
+11.4% upside
Target: $980.73
Annual Revenue & Net Income
RevenueNet Income
'23
$276.71B
$3.56B
'24
$308.95B
$3.00B
'25
$359.05B
$3.29B
'26
$403.43B
$4.76B
Earnings History
Quarter
Actual EPS
Estimate
Result
Aug 2026
$9.93
$9.54
Beat (+4.1%)
May 2026
$11.69
$11.57
Beat (+1.1%)
Feb 2026
$9.34
$9.27
Beat (+0.7%)
Nov 2025
$9.86
$9.05
Beat (+8.9%)
Next Earnings Report
McKesson Corporation is next expected to report earnings on 04 Nov 2026.
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; de…
What is MCK's market cap?
McKesson Corporation has a market capitalization of approximately $102.66B.
What is MCK's P/E ratio?
McKesson Corporation trades at a trailing P/E ratio of 23.5x and a forward P/E of 17.4x, which is below the broad market average of ~25x.
How much revenue does MCK generate?
McKesson Corporation generated $410.98B in trailing 12-month revenue.
What do analysts say about MCK?
The analyst consensus rating for McKesson Corporation is buy, with a mean price target of $980.73. That implies +11.4% upside from the current price.
When does MCK report earnings?
McKesson Corporation is next scheduled to report earnings on 04 Nov 2026.
Does MCK pay a dividend?
Yes. McKesson Corporation pays a dividend with a current yield of 0.42%, at an annual rate of $3.76 per share.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for McKesson Corporation on Apsis Markets.